92 related articles for article (PubMed ID: 22037923)
21. Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours.
Trocòniz IF; Garrido MJ; Segura C; Cendrós JM; Principe P; Peraire C; Obach R
Cancer Chemother Pharmacol; 2006 Jun; 57(6):727-35. PubMed ID: 16261364
[TBL] [Abstract][Full Text] [Related]
22. Oral topotecan in children with recurrent or progressive high-grade glioma: a Phase I/II study by the German Society for Pediatric Oncology and Hematology.
Wagner S; Erdlenbruch B; Längler A; Gnekow A; Kühl J; Albani M; Völpel S; Bucsky P; Emser A; Peters O; Wolff JE
Cancer; 2004 Apr; 100(8):1750-7. PubMed ID: 15073866
[TBL] [Abstract][Full Text] [Related]
23. A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies.
Rizzieri DA; Feldman E; Dipersio JF; Gabrail N; Stock W; Strair R; Rivera VM; Albitar M; Bedrosian CL; Giles FJ
Clin Cancer Res; 2008 May; 14(9):2756-62. PubMed ID: 18451242
[TBL] [Abstract][Full Text] [Related]
24. Results of a phase 1 trial combining ridaforolimus and MK-0752 in patients with advanced solid tumours.
Piha-Paul SA; Munster PN; Hollebecque A; Argilés G; Dajani O; Cheng JD; Wang R; Swift A; Tosolini A; Gupta S
Eur J Cancer; 2015 Sep; 51(14):1865-73. PubMed ID: 26199039
[TBL] [Abstract][Full Text] [Related]
25. Tolerability, safety and pharmacokinetics of ridaforolimus in combination with bicalutamide in patients with asymptomatic, metastatic castration-resistant prostate cancer (CRPC).
Meulenbeld HJ; de Bono JS; Tagawa ST; Whang YE; Li X; Heath KH; Zandvliet AS; Ebbinghaus SW; Hudes GR; de Wit R
Cancer Chemother Pharmacol; 2013 Oct; 72(4):909-16. PubMed ID: 23921574
[TBL] [Abstract][Full Text] [Related]
26. Randomized Phase II Trial of Ridaforolimus in Advanced Endometrial Carcinoma.
Oza AM; Pignata S; Poveda A; McCormack M; Clamp A; Schwartz B; Cheng J; Li X; Campbell K; Dodion P; Haluska FG
J Clin Oncol; 2015 Nov; 33(31):3576-82. PubMed ID: 26077241
[TBL] [Abstract][Full Text] [Related]
27. A phase I study of daily everolimus plus low-dose weekly cisplatin for patients with advanced solid tumors.
Fury MG; Sherman E; Haque S; Korte S; Lisa D; Shen R; Wu N; Pfister D
Cancer Chemother Pharmacol; 2012 Mar; 69(3):591-8. PubMed ID: 21913034
[TBL] [Abstract][Full Text] [Related]
28. A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia.
Gimsing P; Hansen M; Knudsen LM; Knoblauch P; Christensen IJ; Ooi CE; Buhl-Jensen P
Eur J Haematol; 2008 Sep; 81(3):170-6. PubMed ID: 18510700
[TBL] [Abstract][Full Text] [Related]
29. Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors.
O'Donnell A; Faivre S; Burris HA; Rea D; Papadimitrakopoulou V; Shand N; Lane HA; Hazell K; Zoellner U; Kovarik JM; Brock C; Jones S; Raymond E; Judson I
J Clin Oncol; 2008 Apr; 26(10):1588-95. PubMed ID: 18332470
[TBL] [Abstract][Full Text] [Related]
30. A Phase 1 clinical study of temsirolimus (CCI-779) in Japanese patients with advanced solid tumors.
Fujisaka Y; Yamada Y; Yamamoto N; Horiike A; Tamura T
Jpn J Clin Oncol; 2010 Aug; 40(8):732-8. PubMed ID: 20430774
[TBL] [Abstract][Full Text] [Related]
31. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer.
Raymond E; Alexandre J; Faivre S; Vera K; Materman E; Boni J; Leister C; Korth-Bradley J; Hanauske A; Armand JP
J Clin Oncol; 2004 Jun; 22(12):2336-47. PubMed ID: 15136596
[TBL] [Abstract][Full Text] [Related]
32. A multicenter, first-in-pediatrics, phase 1, pharmacokinetic and pharmacodynamic study of ridaforolimus in patients with refractory solid tumors.
Gore L; Trippett TM; Katzenstein HM; Boklan J; Narendran A; Smith A; Macy ME; Rolla K; ; Narashimhan N; Squillace RM; Turner CD; Haluska FG; Nieder M
Clin Cancer Res; 2013 Jul; 19(13):3649-58. PubMed ID: 23659969
[TBL] [Abstract][Full Text] [Related]
33. Phase II evaluation of topotecan for pediatric central nervous system tumors.
Blaney SM; Phillips PC; Packer RJ; Heideman RL; Berg SL; Adamson PC; Allen JC; Sallan SE; Jakacki RI; Lange BJ; Reaman GH; Horowitz ME; Poplack DG; Balis FM
Cancer; 1996 Aug; 78(3):527-31. PubMed ID: 8697400
[TBL] [Abstract][Full Text] [Related]
34. Open-label, non-randomised, inter-individual dose escalation of ZK 304709 with the evaluation of safety, tolerability, pharmacokinetics, oral bioavailability and orientating efficacy after daily administration in patients with advanced cancer (7 d treatment and 14 d recovery).
Graham JS; Plummer R; McCoy C; Kowal K; Wiesinger H; Detjen K; Calvert H; Wiedenmann B; Cassidy J
Eur J Cancer; 2008 Oct; 44(15):2162-8. PubMed ID: 18653327
[TBL] [Abstract][Full Text] [Related]
35. A phase I dose-escalation study of Tivantinib (ARQ 197) in adult patients with metastatic solid tumors.
Rosen LS; Senzer N; Mekhail T; Ganapathi R; Chai F; Savage RE; Waghorne C; Abbadessa G; Schwartz B; Dreicer R
Clin Cancer Res; 2011 Dec; 17(24):7754-64. PubMed ID: 21976535
[TBL] [Abstract][Full Text] [Related]
36. Phase 1 study of dalotuzumab monotherapy and ridaforolimus-dalotuzumab combination therapy in paediatric patients with advanced solid tumours.
Frappaz D; Federico SM; Pearson AD; Gore L; Macy ME; DuBois SG; Aerts I; Iannone R; Geschwindt R; Van Schanke A; Wang R; Geoerger B
Eur J Cancer; 2016 Jul; 62():9-17. PubMed ID: 27185573
[TBL] [Abstract][Full Text] [Related]
37. Phase I clinical and pharmacokinetic study of kahalalide F administered weekly as a 1-hour infusion to patients with advanced solid tumors.
Pardo B; Paz-Ares L; Tabernero J; Ciruelos E; García M; Salazar R; López A; Blanco M; Nieto A; Jimeno J; Izquierdo MA; Trigo JM
Clin Cancer Res; 2008 Feb; 14(4):1116-23. PubMed ID: 18281545
[TBL] [Abstract][Full Text] [Related]
38. A phase I study of ridaforolimus in adult Chinese patients with advanced solid tumors.
Liu L; Zhang W; Li W; Lv F; Xia Z; Zhang S; Liu W; Zandvliet AS; Waajen S; Zhang LX; Yan L; Li J
J Hematol Oncol; 2013 Jul; 6():48. PubMed ID: 23829943
[TBL] [Abstract][Full Text] [Related]
39. Phase I study for ridaforolimus, an oral mTOR inhibitor, in Japanese patients with advanced solid tumors.
Seki Y; Yamamoto N; Tamura Y; Goto Y; Shibata T; Tanioka M; Asahina H; Nokihara H; Yamada Y; Shimamoto T; Noguchi K; Tamura T
Cancer Chemother Pharmacol; 2012 Apr; 69(4):1099-105. PubMed ID: 22143378
[TBL] [Abstract][Full Text] [Related]
40. Phase I pharmacokinetic and pharmacodynamic study of the first-in-class spliceosome inhibitor E7107 in patients with advanced solid tumors.
Eskens FA; Ramos FJ; Burger H; O'Brien JP; Piera A; de Jonge MJ; Mizui Y; Wiemer EA; Carreras MJ; Baselga J; Tabernero J
Clin Cancer Res; 2013 Nov; 19(22):6296-304. PubMed ID: 23983259
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]